SCHEMBL2367175

SCHEMBL2367175

CCCCOC(=O)N[C@@H](CC(=O)O)c1ccc(N(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.57
ALDH1A1 P00352 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
KDM4E B2RXH2 3/20 0.57
HPGD P15428 2/20 0.57
MAPK1 P28482 2/20 0.57
MAPT P10636 1/20 0.57
MCL1 Q07820 1/20 0.57
FAAH O00519 4/20 0.49
GAA P10253 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
FFAR1 O14842 1/20 0.41
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5504818 1.00 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1NPC1RAB9AKDM4E
SCHEMBL5085765 0.86 SMN1; SMN2 (0.50) SMN1; SMN2NPC1RAB9AHPGDMAPK1
SCHEMBL844472 0.86 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL14040614 0.86 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4097623 0.85 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AHPGDMAPK1
SCHEMBL16680706 0.85 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL3663293 0.85 FAAH (0.58) SMN1; SMN2NPC1RAB9AHPGDMAPK1
SCHEMBL2320404 0.85 FAAH (0.59) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL4265545 0.85 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD
SCHEMBL5181827 0.85 KMT2A (0.53) SMN1; SMN2ALDH1A1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076285-B2 Lysobactin amides AICURIS GMBH & CO. KG (DE) 2011-12-13 US disclosed
EP-2007794-B1 LYSOBACTIN AMIDES AICURIS GMBH & CO KG (DE) 2011-09-14 EP disclosed
US-20090203582-A1 LYSOBACTIN AMIDES BAYER HEALTHCARE AG (DE) 2009-08-13 US disclosed
EP-2007794-A1 LYSOBACTIN AMIDES AiCuris GmbH & Co. KG (DE) 2008-12-31 EP disclosed
WO-2007118691-A1 LYSOBACTIN AMIDES AICURIS GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203582-A1 LYSOBACTIN AMIDES AADAT, HAMP, DLST SMN1; SMN2 4112/4885ALDH1A1 3748/4885NPC1 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.